## Review setup

- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report a case-control study of 150 South Indian women with recurrent pregnancy loss (RPL) and 150 non-RPL controls. They identified seven novel single-nucleotide polymorphisms (SNPs) in exons 2 and 7 of the FOXP3 gene, of which four showed significant frequency differences between groups. Bioinformatics modeling and molecular dynamics simulations suggested similar structural features and stability between apo and mutant FOXP3 proteins. The authors conclude that these mutations may disrupt immune-regulatory functions and contribute to RPL.
- **Visible evidence base** Abstract text only; no raw data, sequencing chromatograms, statistical outputs, or simulation details provided
- **Missing materials affecting confidence** Full methods, detailed results with effect sizes and confidence intervals, multiple-testing corrections, population stratification analysis, functional validation data, and structural simulation parameters

## Reviewer

- **Overall assessment** The abstract addresses a clinically relevant question regarding genetic contributors to idiopathic RPL in a South Indian population. The study design is appropriate for exploratory variant discovery, and the focus on FOXP3 is biologically plausible given its role in regulatory T cell function. However, the abstract presents several claims that cannot be adequately evaluated without access to the full manuscript. The statistical robustness of the reported associations is unclear, particularly regarding multiple-testing corrections and potential confounding. The structural and simulation findings appear preliminary and are described in a manner that does not establish functional significance. The conclusion that these variants "can potentially disrupt" immune function is speculative and not directly supported by the presented evidence.
- **Who would be interested in the results, and why** Reproductive immunologists and clinical geneticists studying pregnancy loss would find these results relevant, as they address a poorly understood etiology. Researchers investigating FOXP3 polymorphisms in immune regulation and tolerance may also be interested. Clinicians managing RPL in South Asian populations could view these findings as a step toward population-specific genetic screening, though the clinical utility remains unproven.
- **Major strengths** The study addresses a clinically important and understudied population. The case-control design with a defined control group is appropriate for variant frequency comparisons. The use of Sanger sequencing provides high-confidence variant identification. The inclusion of structural modeling and molecular dynamics simulations represents a reasonable initial approach to assess potential functional impact.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Statistical validity
  - **Claim pointer** "Four SNPs (-11InsT, 206G>A in exon 2, and 433InsT, 726A>T in exon 7), showing significant frequency variations between RPL and NRPL groups"
  - **Evidence pointer** Results section, abstract; location not provided
  - **Concern** The abstract reports significant frequency differences for four SNPs but provides no effect sizes, confidence intervals, p-values, or details on the statistical tests used. With seven variants tested, the risk of false positives from multiple comparisons is substantial, and no correction method is mentioned. The sample size of 150 per group may be underpowered for detecting modest effect sizes, and the abstract does not indicate whether the analysis accounted for potential confounders such as age, parity, or population substructure.
  - **Why it matters** Without robust statistical evidence, the central claim of significant association between these SNPs and RPL cannot be established. False-positive associations in genetic studies are common, especially with small samples and multiple testing, and would undermine the study's contribution.
  - **Resolution test** Provide p-values, odds ratios with confidence intervals, and specify the multiple-testing correction applied. Report whether the associations survive correction and whether sensitivity analyses adjusting for relevant covariates were performed.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Functional interpretation
  - **Claim pointer** "The identified mutations in the FOXP3 gene can potentially disrupt its critical immune-regulatory functions, leading to impaired immune tolerance during pregnancy"
  - **Evidence pointer** Discussion section, abstract; location not provided
  - **Concern** The abstract states that the modeled apo and mutant proteins displayed "similar structural features" and "comparable stability," yet the discussion claims the mutations can disrupt immune-regulatory functions. These statements are contradictory. If the structural and dynamic analyses show no significant differences, there is no basis for inferring functional disruption. No functional assays, such as reporter gene experiments or T cell functional studies, are described.
  - **Why it matters** The conclusion rests on an unsupported leap from sequence variation to functional impact. Without evidence of altered protein function, the clinical relevance of these variants remains speculative, and the study does not meet the standard for establishing a mechanistic link to RPL.
  - **Resolution test** Reconcile the structural findings with the functional claims. Provide functional validation data, such as assays measuring FOXP3 transcriptional activity or regulatory T cell suppressive capacity, or explicitly reframe the conclusions as hypothesis-generating without claiming functional disruption.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** No
  - **Axis** Population genetics and confounding
  - **Claim pointer** "South Indian women with idiopathic RPL" and "150 non-recurrent pregnancy loss (NRPL) controls"
  - **Evidence pointer** Materials and Methods section, abstract; location not provided
  - **Concern** The abstract does not describe how controls were selected, whether they were matched for age and other relevant factors, or whether population stratification was assessed. South India has significant genetic diversity across linguistic and caste groups, and allele frequencies can vary substantially. The absence of population structure analysis raises the risk that observed frequency differences reflect ancestry rather than disease association.
  - **Why it matters** Population stratification is a well-known source of spurious associations in case-control genetic studies. If not addressed, the reported associations may not be reproducible and could mislead subsequent research.
  - **Resolution test** Describe control selection and matching criteria. Report results of population stratification analysis, such as principal component analysis or use of ancestry-informative markers, and adjust for any identified structure in the association analysis.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Reporting completeness
  - **Affected element** Variant nomenclature
  - **Evidence pointer** Results section, abstract; location not provided
  - **Issue** The variant designations "-11InsT" and "433InsT" are not standard HGVS nomenclature. The abstract does not specify the reference sequence used for numbering, which is essential for reproducibility.
  - **Required correction** Use HGVS-compliant nomenclature with the appropriate reference transcript (e.g., NM_014009.4) and specify the genomic or cDNA position clearly.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Clinical relevance
  - **Affected element** Conclusion
  - **Evidence pointer** Conclusion section, abstract; location not provided
  - **Issue** The conclusion states that the findings "underscore the importance of genetic testing" for RPL, but the abstract provides no evidence of clinical utility, such as predictive value or impact on management.
  - **Required correction** Soften the clinical implication or provide evidence from the full manuscript that supports the utility of testing these variants in clinical practice.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Terminology
  - **Affected element** Definition of RPL
  - **Evidence pointer** Introduction section, abstract; location not provided
  - **Issue** The abstract defines RPL as "two or more consecutive pregnancies before 20 weeks of gestation," but international guidelines vary, with some defining RPL as two and others as three or more losses. The choice of definition may affect comparability with other studies.
  - **Required correction** Justify the chosen definition or acknowledge the variability in guidelines and discuss its potential impact on the findings.
- **Technical failings that need to be addressed before the case is established** R1-M1 (statistical validity) and R1-M2 (functional interpretation) are the primary technical failings. The lack of multiple-testing correction and the contradiction between structural similarity and functional disruption claims must be resolved. R1-M3 (population stratification) is also critical for establishing the validity of the genetic association.
- **Assessment against Nature-style criteria** Originality: The study addresses a specific population and gene, but the approach of screening candidate gene variants in RPL is not novel. Scientific importance: The findings could be relevant to understanding RPL genetics, but the current evidence is insufficient to establish a meaningful contribution. Interdisciplinary readership: The topic bridges reproductive medicine and immunogenetics, which may attract readers from both fields, but the abstract does not provide enough depth for either audience. Technical soundness: The sequencing approach is sound, but the statistical and functional analyses are inadequately described and appear insufficient to support the claims. Readability for nonspecialists: The abstract is generally clear, though the variant nomenclature and structural modeling descriptions may be challenging for non-experts.
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents an interesting hypothesis but does not provide sufficient statistical or functional evidence to support the central claims. A revised manuscript with robust statistical analysis, population stratification control, and functional validation, or a more cautious interpretation, would be needed to make the case convincing.

## Risk / unsupported claims

- The claim that four SNPs show "significant frequency variations" is unsupported without p-values, effect sizes, and multiple-testing corrections.
- The claim that mutations "can potentially disrupt" immune-regulatory functions is unsupported given the reported structural similarity and comparable stability between apo and mutant proteins.
- The claim that these findings "underscore the importance of genetic testing" is unsupported without evidence of clinical utility.
- The novelty of the seven SNPs cannot be verified without comparison to existing databases, which is not described in the abstract.
- The functional relevance of the variants to RPL pathogenesis is not established by the presented data.